THE ROLE OF 21-HYDROXYLASE DEFICIENCY IN THE PATHOGENESIS OF BEHCET DISEASE / BEHCET HASTALIGI PATOGENEZINDE 21-HIDROKSILAZ EKSIKLIGININ ROLU.
Behcet disease (BD) is a multisystem inflammatory disorder characterized mainly by recurrent oral and genital aphthous ulcers, skin lesions, and posterior segment uveitis. The etiology of BD is yet unknown, but it is generally considered to be multifactorial with an important contribution of genetic factors and environmental triggers, including microbial agents such as streptococci and herpes viruses (1). HLA-B51 is the strongest genetic susceptibility factor described so far, and several other non-HLA polymorphisms contribute to the tendency for BD phenotype (2). BD has a worse prognosis in young and male patients suggesting a role for sex hormones (3,4). Increased frequency of acne-like lesions and sebum production further supports the contribution of male hormones to the BD pathogenesis (5).
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessively inherited disorders, which are clinically characterized by different degrees of virilization and salt wasting caused by deficiency of enzymes involved in biosynthesis of steroid hormones (6,7). The most common form of CAH is due to mutations in the CYP21A2 gene leading to 21-hydroxylase deficiency, which results in a decrease in cortisol synthesis at varying levels and overproduction of cortisol precursors and sex steroids (6). Classic form of CAH may be life threatening and usually diagnosed very early in life (7). However, patients with non-classic forms of the disease may usually present after puberty, with clinical manifestations such as acne, hirsutism, menstrual disturbances and infertility, reflecting androgen excess instead of adrenal insufficiency (8). Refractory acne may be the main clinical manifestation of those patients. On the other hand, some of the non-classic CAH (NCAH) patients may be asymptomatic and can only be diagnosed during screening of families with affected members (8). Classic CAH patients carry mutations causing severe defects in function such as zero to 5% enzyme activity in both alleles, but about one half to two thirds of patients with NCAH are compound heterozygotes for mutations causing both mild and severe defects in enzyme function (8).
Mutations associated with CAH and NCAH were known to be in linkage disequilibrium with HLA-B alleles, because of strong linkage disequilibrium in the major histocompatibility region (6,9-12). HLA-B51 has been listed among the alleles associated with non-classic CYP21A2 mutations (13,14). Since 21-hydroxylase deficiency associated NCAH is a relatively common autosomal recessive disorder (15), we herein aimed to investigate the possible role of 21-hydroxylase deficiency in linkage disequilibrium with HLA-B51 and causing androgen excess in the pathogenesis of BD, and we included another HLA Class I associated disease with male predominance, ankylosing spondylitis (AS) as disease control group.
MATERIALS AND METHODS
Study group consisted of 18 healthy controls, and 29 patients with BD, who fulfilled the International Study Group Criteria for the diagnosis. Also, 15 patients with AS, who met the modified New York criteria, included into the study. The patient group was selected from Outpatient Clinic as consecutive patients with known HLA status and consenting to participate in the study.
All the patients and healthy controls were clinically evaluated for acne, hirsutism, short stature, premature puberty, menstrual dysfunction and infertility using a standard chart. None of the patients or controls was using glucocorticoids or oral contraceptives that may affect the hormonal evaluation.
All of the patients and healthy controls underwent a diagnostic protocol that included basal serum 17-hydroxyprogesterone (17-OH-P), cortisol, dehydroepiandrosterone sulfate (DHEA-S), total testosterone and sex hormone binding globulin (SHBG) levels and an ACTH-stimulation test. Stimulation test was done by intravenous bolus injection of 0.25 mg 1-24 ACTH (Synacthen; Ciba/Novartis, Basel, Switzerland), and venous blood samples were collected 30 and 60 min later for the measurement of cortisol and 17-OH-P concentrations. All samples were obtained after an overnight fasting, in the early morning between 8 and 9 o'clock and between day 3 and 8 of the menstrual cycle of the female participants. Samples were immediately centrifuged, and serum was separated and frozen at -20oC until analyzed. Informed consent was obtained from all the participants, and Istanbul Faculty of Medicine Research Ethics Committee approved the study protocol.
Serum cortisol levels were measured with Amerlite Cortisol Assay (Ortho-Clinical Diagnostics, Amersham, UK) using a competitive immunoassay technique. Serum 17-OH-P, DHEA-S and testosterone levels were measured with Diagnostic Systems Laboratories (DSL) (Webster, TX) radioimmunoassay kit. SHBG levels were measured with Euro-Diagnostica (Malmo, Sweden) radioimmunoassay (RIA) kit.
Mean values with standard deviation (SD) were calculated, and those values were compared with Student t test for parametric, and Mann-Whitney U test for non-parametric variables. P<0.05 was considered statistically significant for all analyses. Statistical analyses were done by Statistical Package for the Social Sciences for Windows (Release 5.0.1. SPSS Inc.; Chicago, IL, USA).
The mean age ([+ or -]SD) of the healthy controls (8 females/10 males) was 29[+ or -]5.3 (range, 22-40), of BD patients (14 females/15 males) was 41[+ or -]9.6 (range, 24-60), of AS patients (3 females/12 males) was 29[+ or -]8.7 (range, 16-44). Only 8 out of 29 patients with BD and 1 out of 15 patient with AS had acne or history of acne.
According to the current approach (7,15), we accepted 10 ng/mL concentration of 17-OH-P as the cut-off point to define NCAH. After ACTH stimulation 3 of BD patients (10.3%) and 5 AS patients (33.3%) had increased 17-OH-P concentrations >10 ng/mL. Clinical and laboratory features of those BD and AS patients are given in Table 1. Two of the BD patients (66.6%) were HLA-B51 positive, and four of the AS patients (80%) were HLA-B27 positive (Table 2). Two of AS patients were also carrying HLA-B51.
In one of the healthy controls with high basal level (3.4 ng/mL), 17-OH-P value was found to be 9.9 ng/mL after stimulation, and his result was considered as borderline positive.
Those 3 patients with BD, 5 patients with AS and one of healthy controls were considered as NCAH or possible heterozygous carriers of CYP21A2 mutations for CAH. Mean total testosterone levels of BD patients were significantly lower than those of healthy controls, however these levels were within normal limits in BD patients with high stimulated 17-OH-P (Table 2).
This preliminary study identified 10.3% of the BD and 33.3% of the AS patients with high 17-OH-P levels following ACTH stimulation. High 17-OH-P levels suggesting 21-hydroxylase deficiency was observed in 37.5% of the BD patients with prominent acne, and just one out of 15 AS patients with acne also had high stimulated 17-OH-P levels.
Potential contribution of 21-hydroxylase deficiency associated androgen excess has not been studied in BD and AS, despite their very strong association with HLA Class I antigens, B51 and B27, respectively. This study is the first one aiming to test the possibility of HLA haplotype associated CYP21A variants as a pilot work. Therefore, it has several limitations, especially regarding the number of subjects studied and also use of single method, the ACTH stimulation test, as a screening tool.
The prevalence of NCAH is relatively high among females with hirsutism or polycyctic ovary syndrome (7,15-20), however there is no data about the frequency of mutation carriers in Turkish healthy population. On the other hand, screening methods based on basal 17-OH-P levels have limitations, and some patients with less than suggested 17-OH-P concentration of 2 ng/mL may have >10 ng/mL values after ACTH stimulation, similar to one of the AS patients in the study group (21,22).
There are also different views on the cut-off concentration of stimulated 17-OH-P to define NCAH, mainly due to variations in the main aims of definitions. Current suggestion of >10 ng/mL 17-OH-P is usually regarded as a sensitive level for capturing a larger group, but its specificity may be lower compared to the cut-off values such as 14 or even 15 ng/mL concentration of 17-OH-P after ACTH stimulation, which reaches almost 100% specificity (7,8,15,22,23).
The main aim of this study was investigation of the possibility of 21-hydroxylase deficiency in linkage disequilibrium with HLA-B51 in BD patients with manifestations suggesting androgen access. But, higher frequency of positive results in AS patients without prominent acne or other androgen excess manifestations may require further investigations. It is necessary to note that it may be hard to detect androgen excess findings in male patients, which explains the ascertainment bias in favor of diagnosis of mainly female patients (8). On the other hand, when we accept 14 ng/L 17-OH-P level as the cutoff point, only one patient with BD, who had prominent acne and carrying HLA-B51 allele, could be diagnosed as NCAH.
Regarding the sex hormone levels in AS and BD, inconsistent results have been reported similar to unexpectedly low total testosterone levels we observed in BD patients in this study (5,24,25). However, relatively higher total testosterone levels in those patients with high 17-OH-P levels can be regarded as a supporting evidence for the functional significance of ACTH-stimulation results.
The results of current study showing 10.3% of BD and 33.3% of AS patients with high ACTH-stimulated 17-OH-P levels warrant further analysis to screen CYP21A2 mutations in linkage disequilibrium with HLA-B51 and HLA-B27 by genetic methods, to confirm their role in the development of male predominant disorders.
Ethics Committee Approval: Ethics committee approval was received for this study from the Ethics Committee of Istanbul University Istanbul Faculty of Medicine.
Informed Consent: Informed consent was obtained from all participants who participated in this study.
Peer-review: Externally peer-reviewed.
Author Contributions: Concept--N.G., A.G., F.A.; Design--N.G., A.G., F.A..; Supervision--O.A., L.O., F.A., ; Resources - A.G., M.I., L.O.; Materials - N.G.; Data Collection and/or Processing--N.G., A.G., M.I. , L.O.; Analysis and/or Interpretation - N.G., A.G., F.A.; Literature Search--N.G., A.G.; Writing Manuscript - N.G., A.G., F.A.; Critical Review - N.G., A.G., M.I., L.O., O.A., F.A.
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: This project was supported by the Research Fund of Istanbul University (Project number: T-480/071197). Synacthen vials were kindly provided by Ciba/Novartis.
Etik Komite Onayi: Bu calisma icin etik komite onayi Istanbul Universitesi Tip Fakultesi'nden alinmistir.
Hasta Onami: Hasta onami bu calismaya katilan tum katilimcilardan alinmistir.
Hakem Degerlendirmesi: Dis bagimsiz.
Yazar Katkilari: Fikir - N.G., A.G., F.A.; Tasarim - N.G., A.G., F.A..; Denetleme--O.A., L.O., F.A., ; Kaynaklar - A.G., M.I., L.O.; Malzemeler - N.G.; Veri Toplanmasi ve/veya Islemesi - N.G., A.G., M.I., L.O.; Analiz ve/veya Yorum - N.G., A.G., F.A.; Literatur Taramasi - N.G., A.G.; Yaziyi Yazan - N.G., A.G., F.A.; Elestirel Inceleme - N.G., A.G., M.I., L.O., O.A., F.A.
Cikar Catismasi: Yazarlar cikar catismasi bildirmemislerdir.
Finansal Destek: Bu calisma Istanbul Universitesi Bilimsel Arastirma Projeleri Koordinatorlugu tarafindan desteklenmistir (Yeni saglik kod T-480/071197). Synacthen ampulleri Ciba/Novartis tarafindan bagislanmistir.
(1.) Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol 2015;37(4):413-8. [CrossRef]
(2.) Gul A. Genetics of Behcet's disease: lessons learned from genomewide association studies. Curr Opin Rheumatol 2014;26(1):56-63. [CrossRef]
(3.) Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis 1984;43(6):783-9. [CrossRef]
(4.) Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138(3):373-80. [CrossRef]
(5.) Yazici H, Mat C, Deniz S, Iscimen A, Yurdakul S, Tuzun Y, et al. Sebum production is increased in Behcet's syndrome and even more so in rheumatoid arthritis. Clin Exp Rheumatol 1987;5(4):371-4.
(6.) Dupont B, Oberfield SE, Smithwick EM, Lee TD, Levine LS. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 1977;2 (8052-8053):1309-12. [CrossRef]
(7.) Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95(9):4133-60. [CrossRef]
(8.) Witchel SF, Azziz R. Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010;2010:625105. [CrossRef]
(9.) Levine LS, Zachmann M, New MI, Prader A, Pollack MS, O'Neill GJ, et al. Genetic mapping of the 21-hydroxylase-deficiency gene within the HLA linkage group. N Engl J Med 1978;299(17):911-5. [CrossRef]
(10.) Bercovici JP, Khoury S, Le Fur JM, Saleun JP, Nahoul K, Scholler R. Hormonal profiles of heterozygotes in humans for 21-hydroxylase deficiency defined by HLA B typing. J Steroid Biochem 1981;14(10):1049-54. [CrossRef]
(11.) Pollack MS, Keenan B, Christiansen FT, Cobain TJ, Dawkins RL, Clayton G. The immunological detection of a 21-OH deficiency mutation HLA supratype. Am J Hum Genet 1986;38(5):688-98.
(12.) White PC, Werkmeister J, New MI, Dupont B. Steroid 21-hydroxylase deficiency and the major histocompatibility complex. Hum Immunol 1986;15(4):404-15. [CrossRef]
(13.) Velasco FJ, Pico AM, Munoz C, Mauri M, de la Sen ML. [A genetic and hormonal study of 5 patients with the nonclassical form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. Med Clin (Barc) 1992;99(3):81-6.
(14.) Parlato F, Pisano G, Misiano G, Cosentini E, Cacciapuoti C, Cavalcanti MR, et al. HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region. J Endocrinol Invest 1992;15(6):429-36. [CrossRef]
(15.) Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimur F, Moran C, Oberfield S, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017;23 (5):580-99. [CrossRef]
(16.) Sahin Y, Kelestimur F. The frequency of late-onset 21-hydroxylase and 11 beta-hydroxylase deficiency in women with polycystic ovary syndrome. Eur J Endocrinol 1997;137(6):670-4. [CrossRef]
(17.) Yarman S, Dursun A, Oguz F, Alagol F. The prevalence, molecular analysis and HLA typing of late-onset 21-hydroxylase deficiency in Turkish woman with hirsutism and polycystic ovary. Endocr J 2004;51(1):31-6. [CrossRef]
(18.) Unluhizarci K, Kula M, Dundar M, Tanriverdi F, Israel S, Colak R, et al. The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. Gynecol Endocrinol 2010;26(2):139-43. [CrossRef]
(19.) Binay C, Simsek E, Cilingir O, Yuksel Z, Kutlay O, Artan S. Prevalence of nonclassic congenital adrenal hyperplasia in Turkish children presenting with premature pubarche, hirsutism, or oligomenorrhoea. Int J Endocrinol 2014;2014:768506. [CrossRef]
(20.) Kirac D, Guney AI, Akcay T, Guran T, Ulucan K, Turan S, et al. The frequency and the effects of 21-hydroxylase gene defects in congenital adrenal hyperplasia patients. Ann Hum Genet 2014;78(6):399-409. [CrossRef]
(21.) Escobar-Morreale HF, Sanchon R, San Millan JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93(2):527-33. [CrossRef]
(22.) Ghizzoni L, Cappa M, Vottero A, Ubertini G, Carta D, Di Iorgi N, et al. Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche. Eur J Endocrinol 2011;165 (2):307-14. [CrossRef]
(23.) Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994;78(4):810-5. [CrossRef]
(24.) Gooren LJ, Giltay EJ, van Schaardenburg D, Dijkmans BA. Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheum Dis Clin North Am 2000;26(4):969-87. [CrossRef]
(25.) Gerencer M, Tajic M, Kerhin-Brkljacic V, Kastelan A. An association between serum testosterone level and HLA phenotype. Immunol Lett 1982;4(3):155-8. [CrossRef]
Nurdan GUL (*), Ahmet GUL (**), Murat INANC (**), Lale OCAL (**), Orhan ARAL (**), Faruk ALAGOL (*)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, (*) Division of Endocrinology and Metabolism and (**) Division of Rheumatology, Istanbul, Turkey
(Iletisim kurulacak yazar/Corresponding author: email@example.com)
Date received/Dergiye geldigi tarih: 05.02.2018 - Date accepted/Dergiye kabul edildigi tarihi: 19.02.2018
Table 1. Clinical and laboratory features of 3 Behcet disease and 5 ankylosing spondylitis patients with high 17-OH-P results after ACTH stimulation 17-OH-P Patient Age Sex Acne Total T SHBG DHEAS (ng/mL) (ng/mL) (nmol/L) ([micro]g/dL) Basal Behcet disease 1 26 M Yes 8.0 134.8 62.3 5.3 2 24 M Yes 8.2 80 266.9 8.8 3 36 M Yes 6.3 46.5 323.8 4.8 Ankylosing spondylitis 1 41 M No 12.3 81.4 547.5 5.5 2 20 M No 11.1 46.0 149.2 7.1 3 44 M No 3.7 39.0 283 1.8 4 27 M No 7.1 28.8 425.8 2.9 5 19 M Yes 13.3 39.8 296.8 3.8 17-OH-P (ng/mL) Patient Stimulated HLA-B Allele Behcet disease 1 11.2 B35/B35 2 14.8 B51/B45-50? 3 13 B51/B55 Ankylosing spondylitis 1 13.3 B27 2 12.2 B27 3 11.5 B51/B57 4 11.0 B51/B27 5 10.1 B27 17-OH-P: 17-OH-progesterone; ACTH: adrenocorticotropic hormone; T: testosterone; SHBG: sex hormone binding globulin; DHEAS: dehydroepiandrosterone sulfate; HLA: human leukocyte antigen Table 2. Serum testosterone, SHBG and DHEAS concentrations in the study group Testosterone (ng/mL)[+ or -]SD Male Female Healthy controls 6.7[+ or -]1.6 0.8[+ or -]0.3 Behcet disease 4.9[+ or -]1.7 (*) 0.4[+ or -]0.3 (**) Ankylosing spondylitis 7.5[+ or -]3.4 0.8[+ or -]0.3 SHBG DHEAS (nmol/L)[+ or -]SD (nmol/L)[+ or -]SD Healthy controls 74.4[+ or -]48.3 263.9[+ or -]146.8 Behcet disease 81.0[+ or -]70.8 191.2[+ or -]115 Ankylosing spondylitis 58.0[+ or -]46.8 287.4[+ or -]125.5 (*) p=0.0083, (**) p=0.0174. SHBG: sex hormone binding globulin; DHEAS: dehydroepiandrosterone sulfate
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CLINICAL RESEARCH/KLINIK ARASTIRMA|
|Author:||Gul, Nurdan; Gul, Ahmet; Inanc, Murat; Ocal, Lale; Aral, Orhan; Alagol, Faruk|
|Publication:||Journal of Istanbul Faculty of Medicine|
|Date:||Mar 1, 2018|
|Previous Article:||ENDOVASKULER AORT ANEVRIZMA TAMIRI: ERKEN VE GEC DONEM VASKULER KOMPLIKASYONLARI / VASCULAR COMPLICATIONS OF ENDOVASCULAR AORTIC ANEURISM REPAIR:...|
|Next Article:||TITANYUM DIOKSIT NANOPARCACIKLARININ YAC-1 LENFOMA HUCRE SOYU CANLILIGI VE INCE YAPISI UZERINE ETKILERI / THE EFFECTS OF TITANIUM DIOXIDE...|